## The Effect of Copper (II) Sulfate Pentahydrate Concentration on Locomotor Ability and Lifespan of Transgenic Alzheimer's Model Drosophila melanogaster

Davidson, Lauren (School: Harrison High School)

Alzheimer's Disease (AD) is a progressive neurodegenerative disease believed to be caused by the abnormal breakdown of proteins creating toxic A $\beta$  plaques. Copper is naturally occurring in the brain and is required for maintaining the health of neurons. Two conflicting theories on copper interaction with AD exist: 1. A $\beta$  plaques absorb Cu2+ ions, creating a Cu2+ deficiency in neurons, decreasing neuronal function 2. Excess Cu2+ in the brain binds to A $\beta$ , increasing aggregation, causing an increase in neurodegeneration. This study researched the effects of Cu2+ concentration on transgenic Drosophila melanogaster using a GAL4-UAS system expressing the human "Arctic" A $\beta$ 42 mutation to determine if supplementation could decrease AD-associated effects. A dose-response study was conducted by adding 0, 1, 10, 100, 500, and 1000 µ<sup> $\Box$ </sup> concentrations of CuSO4.5H2O to Instant Drosophila Medium Blue. AD has progressive deterioration of movement coordination over time so a negative geotaxis assay was conducted on days 7, 8, and 9 of life to measure neurological function. Probability of survival was documented using Kaplan-Meier curves. Results showed that as Cu2+ concentration increased, locomotor ability of Arctic flies increased significantly (p<.05), while that of wildtype and Gal4 controls generally decreased. Arctic flies had normalization of lifespan with no significant difference in lifespan existing between 10 µ<sup> $\Box$ </sup> Arctic and 0 µ<sup> $\Box$ </sup> wildtype flies (p>.05). These results imply that Cu2+ supplementation had an ameliorative effect on neurological function and lifespan of transgenic Drosophila melanogaster imply that Cu2+ supplementation had an ameliorative effect on neurological function and lifespan of transgenic Drosophila melanogaster suggesting that Cu2+ supplementation may have an improving effect in AD patients.